Neovacs S.A. (EPA:ALNEV)
France
· Delayed Price · Currency is EUR 0.0276
+0.0142 (105.97%)
Apr 29, 2025, 9:45 AM CET
Neovacs Company Description
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France.
It develops treatments for autoimmune diseases using its Kinoid technology. The company’s product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of lupus erythematosus; and Phase IIa clinical trial for the treatment of dermatomyositis; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies.
The company was founded in 1993 and is based in Paris, France.
Neovacs S.A.
| Country | France |
| Founded | 1993 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Hugo Brugiere |
Contact Details
Address: 3-5, Impasse Reille Paris, 75014 France | |
| Website | neovacs.com |
Stock Details
| Ticker Symbol | ALNEV |
| Exchange | Euronext Paris |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | FR00140077X1 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Hugo Brugiere M.Sc. | Chairman, GM and Chief Executive Officer |
| Prof. Daniel Zagury | Founder, Chairman of Scientific Research Committee and Director |
| Vincent Serra Ph.D. | Scientific and Operational Director |
| Alexandre Courtoux | Administrative and Financial Director |
| Charlene Masson | Corporate Communication and Investor Relations |